SenzaGen AB Market Cap ($15.15 Million)
Market Cap & Net Worth: SenzaGen AB (SENZA)
SenzaGen AB market cap. SenzaGen AB (ST:SENZA) has a market capitalization of $15.15 Million (Skr140.73 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25796 globally and #526 in its home market, demonstrating a 9.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SenzaGen AB's stock price Skr4.77 by its total outstanding shares 29504026 (29.50 Million). Also see SenzaGen AB operating cash flow efficiency for how efficiently the company converts equity into cash flow.
SenzaGen AB Market Cap History (2017–2026)
SenzaGen AB market cap history from 2017 to 2026. Data shows change from $107.95 Million to $15.15 Million (-21.47% CAGR). Check SenzaGen AB (SENZA) stock price for real-time trading data and today's change.
Index Memberships
SenzaGen AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.32 Billion | 0.10% | #123 of 281 |
Weight: SenzaGen AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SenzaGen AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SenzaGen AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is SenzaGen AB growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.38x
SenzaGen AB's market cap is 0.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $107.95 Million | $1.15 Million | -$12.99 Million | 93.63x | N/A |
| 2018 | $103.13 Million | $2.00 Million | -$16.09 Million | 51.64x | N/A |
| 2019 | $59.25 Million | $2.72 Million | -$50.24 Million | 21.75x | N/A |
| 2020 | $41.59 Million | $7.96 Million | -$27.32 Million | 5.23x | N/A |
| 2021 | $31.75 Million | $15.42 Million | -$31.35 Million | 2.06x | N/A |
| 2022 | $38.26 Million | $41.77 Million | -$24.91 Million | 0.92x | N/A |
| 2023 | $23.11 Million | $49.87 Million | -$22.10 Million | 0.46x | N/A |
| 2024 | $21.91 Million | $57.70 Million | -$17.85 Million | 0.38x | N/A |
Competitor Companies of SENZA by Market Capitalization
Companies near SenzaGen AB in the global market cap rankings as of November 5, 2026. Also see SenzaGen AB assets under control for a full breakdown of the balance sheet.
Key companies related to SenzaGen AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #86 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #138 globally with a market cap of $165.94 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #479 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #505 globally with a market cap of $53.86 Billion USD ( CN¥368.05 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #86 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $706.16 |
| #138 | Danaher Corporation | NYSE:DHR | $165.94 Billion | $234.93 |
| #479 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $391.03 |
| #505 | WuXi AppTec Co Ltd | SHG:603259 | $53.86 Billion | CN¥148.81 |
Market Capitalization of SenzaGen AB (2017–2026)
Market capitalization of SenzaGen AB from 2017 to today. Between 2017 and today, SenzaGen AB's market cap moved from $107.95 Million to $ 15.15 Million, with a yearly change of -21.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr15.15 Million | -21.55% |
| 2025 | Skr19.30 Million | -11.88% |
| 2024 | Skr21.91 Million | -5.22% |
| 2023 | Skr23.11 Million | -39.59% |
| 2022 | Skr38.26 Million | +20.50% |
| 2021 | Skr31.75 Million | -23.66% |
| 2020 | Skr41.59 Million | -29.80% |
| 2019 | Skr59.25 Million | -42.55% |
| 2018 | Skr103.13 Million | -4.47% |
| 2017 | Skr107.95 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of SenzaGen AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.15 Million USD |
| MoneyControl | $15.15 Million USD |
| MarketWatch | $15.15 Million USD |
| marketcap.company | $15.15 Million USD |
| Reuters | $15.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more